IL7R and acute lymphoblastic leukemia: Here, we developed and characterized a fully human monoclonal antibody against IL-7Rα, providing clear proof-of-concept for the development of antibody-based treatments for T-ALL and other cancers relying on IL-7/IL-7R-mediated signals.